Children who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.

Odyssey Therapeutics (ODTX), which is developing treatments for inflammatory bowel disease, has filed for a $100M initial ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Lilly's Omvoh receives US FDA approval to treat Crohn's disease in adults: Indianapolis Friday, January 17, 2025, 12:00 Hrs [IST] Eli Lilly and Company announced that the US Food ...

Our gut is a bustling hub of activity, home to trillions of microbes that work together with our bodies to keep us healthy. A recent study explores one fascinating aspect of this partnership: how gut ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal ...